| Size | Price | Stock | Qty |
|---|---|---|---|
| 10g |
|
||
| Other Sizes |
| Targets |
Iminodiacetic acid acts as a metal ion chelator, binding transition metals through its carboxyl and imino groups. It is a bidentate ligand that strongly binds transition metals. It is used as an inhibitor of bovine liver glutamate dehydrogenase. It can be used as a biomarker to predict the severity of ARDS (acute respiratory distress syndrome).
|
|---|---|
| ln Vitro |
In vitro, Iminodiacetic acid is a metal ion chelator that selectively and irreversibly binds metal ions. It reduces the toxicity of metal ions and promotes their adsorption and separation. It is used as an inhibitor of bovine liver glutamate dehydrogenase. It can be used in the preparation of iminodiacetic acid (IDA)-type adsorbent for protein purification.
|
| ln Vivo |
In vivo, Iminodiacetic acid can be used as a biomarker to predict the severity of ARDS (acute respiratory distress syndrome). It may be utilized to remove toxic metal ions from water. Detailed in vivo pharmacological data are limited in the available literature.
|
| Enzyme Assay |
Iminodiacetic acid's metal chelation activity can be characterized using metal binding assays. The compound's ability to bind metal ions such as Cr⁶⁺, Cd²⁺, Ni²⁺, and Pb²⁺ is assessed using spectroscopic or chromatographic methods. Its inhibition of glutamate dehydrogenase is measured using standard enzyme assays.
|
| Cell Assay |
In vitro cell experiments with Iminodiacetic acid involve treating cells with the compound and assessing its effects on metal ion toxicity and cellular function. The compound's ability to reduce metal ion toxicity is evaluated in cell-based assays.
|
| Animal Protocol |
In vivo animal studies with Iminodiacetic acid have not been extensively reported in the available literature. The compound is primarily used as a chelating agent and research reagent. Further studies are needed to evaluate its in vivo effects.
|
| ADME/Pharmacokinetics |
Absorption, Distribution and Excretion
This study investigated the permeability and transport of lead nitrate alone and after chelation with iminodiacetic acid (PBIDA) in the rat placenta. The results showed that the PBIDA complex had little or no effect on maternal blood or fetal lead levels. Pharmacokinetic data for Iminodiacetic acid are not available in the searched literature. As a small molecule with a molecular weight of 133.10 g/mol, the compound is expected to be rapidly excreted. |
| Toxicity/Toxicokinetics |
Iminodiacetic acid is considered safe for research use at typical concentrations. As a research compound and chelating agent, it is intended for laboratory use only and not for human consumption. Standard laboratory safety practices should be followed.
|
| References |
|
| Additional Infomation |
IgA is an aminodicarboxylic acid, a derivative of glycine, in which a hydrogen atom bonded to a nitrogen atom is replaced by a carboxymethyl group. It is a chelating agent. It is a derivative of glycine, an aminodicarboxylic acid, and also a non-protein α-amino acid. It is the conjugate acid of IgA. IgA has been reported in Pogostemon cablin, and relevant data are available. Mechanism of Action: Pregnant rats were given lead nitrate alone or in combination with different chelating agents, including IgA, on days 9, 11, or 16 of gestation. The lead chelate complexes reduced or offset the overall toxicity in the embryo or fetus, but did not enhance it. There was no significant difference in properties between chelated lead and lead alone. Chelating agents were more effective after day 9 than on days 11 or 16. EDTA had the greatest reducing effect on the overall effect, while IDA provided the least protection.
Iminodiacetic acid has a molecular formula of C₄H₇NO₄ and a molecular weight of 133.10 g/mol. Purity is typically ≥98%. It is a metal ion chelator targeting Cr⁶⁺, Cd²⁺, Ni²⁺, and Pb²⁺. It is used as an inhibitor of bovine liver glutamate dehydrogenase and can be used as a biomarker for ARDS. |
| Molecular Formula |
C4H7NO4
|
|---|---|
| Molecular Weight |
133.1027
|
| Exact Mass |
133.037
|
| CAS # |
142-73-4
|
| Related CAS # |
31685-59-3 (unspecified hydrochloride salt);928-72-3 (di-hydrochloride salt)
|
| PubChem CID |
8897
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
370.6±27.0 °C at 760 mmHg
|
| Melting Point |
243 °C (dec.)(lit.)
|
| Flash Point |
177.9±23.7 °C
|
| Vapour Pressure |
0.0±1.8 mmHg at 25°C
|
| Index of Refraction |
1.501
|
| LogP |
-1.4
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
9
|
| Complexity |
108
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
NBZBKCUXIYYUSX-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C4H7NO4/c6-3(7)1-5-2-4(8)9/h5H,1-2H2,(H,6,7)(H,8,9)
|
| Chemical Name |
2-(carboxymethylamino)acetic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ≥ 10 mg/mL (~75.13 mM)
DMSO :< 1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 7.5131 mL | 37.5657 mL | 75.1315 mL | |
| 5 mM | 1.5026 mL | 7.5131 mL | 15.0263 mL | |
| 10 mM | 0.7513 mL | 3.7566 mL | 7.5131 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
